Literature DB >> 21401864

Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting.

J Dragun1, S Pérez-Del-Pulgar, G Crespo, S Ramírez, M Coto-Llerena, L Mensa, J C García-Valdecasas, M Navasa, X Forns.   

Abstract

Neutralizing antibody (nAb) activity during the course of natural infection is believed to be crucial to combating virus propagation. The aim of this study was to measure the impact of nAb response on HCV early kinetics and genetic evolution in the liver transplantation (LT) setting. A cohort of 28 patients undergoing LT for HCV-related cirrhosis was included in the study. Viral load, nAb titers and hypervariable region 1 (HVR1) sequences were determined in serum samples obtained before and at different time points after LT. Serum nAb titers were assessed using HCV pseudoparticles (HCVpp). HVR1 sequences were obtained by direct sequencing. Patients were classified according to viral kinetic patterns (plateau or increasing), during the first week after LT. All patients demonstrated high titers of nAbs before LT, although this was not associated with early kinetic patterns or HVR1 evolution during the first week after LT. We found that in patients with plateau HCV early kinetics, the virus required adaptive mutations, while in those with increasing viral loads, the HVR1 region remained largely conserved (p = 0.015). These data suggest that HCV adaptation via selection of the best-fitted variants may account for early viral kinetics following LT. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21401864     DOI: 10.1111/j.1600-6143.2011.03440.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation.

Authors:  Weihua Wang; Jianguo Lin; De Tan; Yanjuan Xu; Elizabeth M Brunt; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  Biochem Biophys Res Commun       Date:  2011-09-16       Impact factor: 3.575

2.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

3.  HCV in liver transplantation.

Authors:  Giacomo Germani; Emmanuel Tsochatzis; Vasilios Papastergiou; Andrew K Burroughs
Journal:  Semin Immunopathol       Date:  2012-07-25       Impact factor: 9.623

4.  Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.

Authors:  Ian A Rowe; Damien C Tully; Matthew J Armstrong; Richard Parker; Kathy Guo; Darren Barton; Gene D Morse; Charles S Venuto; Colin B Ogilvie; Ditte L Hedegaard; Jeffrey F McKelvy; Flossie Wong-Staal; Todd M Allen; Peter Balfe; Jane A McKeating; David J Mutimer
Journal:  Liver Transpl       Date:  2016-03       Impact factor: 5.799

5.  Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.

Authors:  George Koutsoudakis; Jakub Dragun; Sofia Pérez-Del-Pulgar; Mairene Coto-Llerena; Laura Mensa; Gonzalo Crespo; Patricia González; Miquel Navasa; Xavier Forns
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

6.  A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus.

Authors:  George Koutsoudakis; Sofía Pérez-del-Pulgar; Patricia González; Gonzalo Crespo; Miquel Navasa; Xavier Forns
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.